Peter Doshi

5.7k total citations · 2 hit papers
91 papers, 3.0k citations indexed

About

Peter Doshi is a scholar working on Epidemiology, Public Health, Environmental and Occupational Health and Pharmacology. According to data from OpenAlex, Peter Doshi has authored 91 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Epidemiology, 26 papers in Public Health, Environmental and Occupational Health and 22 papers in Pharmacology. Recurrent topics in Peter Doshi's work include Influenza Virus Research Studies (28 papers), Pharmaceutical industry and healthcare (20 papers) and Meta-analysis and systematic reviews (14 papers). Peter Doshi is often cited by papers focused on Influenza Virus Research Studies (28 papers), Pharmaceutical industry and healthcare (20 papers) and Meta-analysis and systematic reviews (14 papers). Peter Doshi collaborates with scholars based in United States, United Kingdom and Australia. Peter Doshi's co-authors include Tom Jefferson, Mark Jones, Chris Del Mar, Carl Heneghan, Rokuro Hama, Matthew Thompson, T. Jefferson, Igho Onakpoya, Elizabeth Spencer and Liz Dooley and has published in prestigious journals such as The Lancet, Annals of Internal Medicine and American Journal of Public Health.

In The Last Decade

Peter Doshi

89 papers receiving 2.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children

2012 432 citations Tom Jefferson, Mark Jones et al. profile →
Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults

2022 111 citations Mark Jones, Peter Doshi et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Peter Doshi	1.4k	669	475	353	323	91	3.0k
Ross Harris	1.5k 1.1×	1.4k 2.1×	294 0.6×	178 0.5×	198 0.6×	68	3.9k
Susan S. Ellenberg	833 0.6×	613 0.9×	751 1.6×	857 2.4×	535 1.7×	168	6.1k
Jennifer C. Nelson	1.5k 1.1×	914 1.4×	273 0.6×	251 0.7×	63 0.2×	93	4.2k
Vittorio Demicheli	2.9k 2.2×	869 1.3×	319 0.7×	232 0.7×	131 0.4×	87	4.2k
Antoni Trilla	863 0.6×	763 1.1×	289 0.6×	160 0.5×	61 0.2×	143	3.2k
Gabriel Rada	421 0.3×	592 0.9×	617 1.3×	597 1.7×	252 0.8×	169	3.7k
Marta Gwinn	1.0k 0.8×	1.2k 1.7×	933 2.0×	272 0.8×	130 0.4×	124	5.6k
Shinn‐Jang Hwang	2.5k 1.8×	386 0.6×	805 1.7×	332 0.9×	33 0.1×	260	6.5k
Ann Marie Návar	920 0.7×	310 0.5×	515 1.1×	977 2.8×	44 0.1×	167	5.4k
Robert Ball	1.2k 0.9×	1.1k 1.6×	337 0.7×	300 0.8×	68 0.2×	130	4.3k

Countries citing papers authored by Peter Doshi

Since Specialization

Citations

This map shows the geographic impact of Peter Doshi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Doshi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Doshi more than expected).

Fields of papers citing papers by Peter Doshi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Doshi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Doshi. The network helps show where Peter Doshi may publish in the future.

Co-authorship network of co-authors of Peter Doshi

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Doshi. A scholar is included among the top collaborators of Peter Doshi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Doshi. Peter Doshi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Doshi, Peter. (2025). Ticagrelor doubts: inaccuracies uncovered in key studies for AstraZeneca’s billion dollar drug. BMJ. 389. r1201–r1201. 1 indexed citations

Qureshı, Riaz, Evan Mayo‐Wilson, Matthew J. Page, et al.. (2024). Development and Evaluation of a Framework for Identifying and Addressing Spin for Harms in Systematic Reviews of Interventions. Annals of Internal Medicine. 177(8). 1089–1098. 1 indexed citations

Jones, Mark, et al.. (2023). Sources of bias in observational studies of covid‐19 vaccine effectiveness. Journal of Evaluation in Clinical Practice. 30(1). 30–36. 22 indexed citations

Doshi, Peter. (2023). Did the FDA break its own rules in approving the antibiotic Recarbrio?. BMJ. 381. p1048–p1048. 3 indexed citations

Doshi, Peter. (2023). The FDA and Moderna’s cosy relationship: how lax rules enable a revolving door culture. BMJ. 383. p2486–p2486.

Powers, John H., et al.. (2020). Antibiotics Approved for Marketing in Populations Specifically Excluded From Premarketing Trials, 1999–2018. Mayo Clinic Proceedings. 95(12). 2699–2703. 3 indexed citations

Doshi, Peter. (2020). Covid-19 vaccine trial protocols released. BMJ. 371. m4058–m4058. 26 indexed citations

Jørgensen, Lars, Peter Doshi, Peter C Gøtzsche, & Tom Jefferson. (2018). Challenges of independent assessment of potential harms of HPV vaccines. BMJ. 362. k3694–k3694. 12 indexed citations

Doshi, Peter & Tom Jefferson. (2016). Open data 5 years on: a case series of 12 freedom of information requests for regulatory data to the European Medicines Agency. Trials. 17(1). 78–78. 20 indexed citations

10.

Doshi, Peter. (2015). No correction, no retraction, no apology, no comment: paroxetine trial reanalysis raises questions about institutional responsibility. BMJ. 351. h4629–h4629. 13 indexed citations

11.

Persaud, Nav & Peter Doshi. (2015). North American regulatory agencies can and should make clinical trial data publicly available. Canadian Medical Association Journal. 188(2). 96–97. 5 indexed citations

12.

Jefferson, Tom & Peter Doshi. (2014). Un fallimento multisistemico: la storia dei farmaci antinfluenzali. Recenti Progressi in Medicina. 105(5). 187–90. 1 indexed citations

13.

Jones, Mark, Tom Jefferson, Peter Doshi, et al.. (2014). Commentary on Cochrane review of neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Clinical Microbiology and Infection. 21(3). 217–221. 9 indexed citations

14.

Doshi, Peter & Tom Jefferson. (2013). Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. BMJ Open. 3(2). e002496–e002496. 57 indexed citations

15.

Doshi, Peter. (2013). Influenza Vaccines. JAMA Internal Medicine. 173(11). 1014–1014. 6 indexed citations

16.

Doshi, Peter, Tom Jefferson, & Chris Del Mar. (2012). The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience. PLoS Medicine. 9(4). e1001201–e1001201. 119 indexed citations

17.

Doshi, Peter, Mark Jones, & T. Jefferson. (2012). Rethinking credible evidence synthesis. BMJ. 344(jan17 2). d7898–d7898. 41 indexed citations

18.

Jefferson, T., et al.. (2011). Ensuring safe and effective drugs: who can do what it takes?. BMJ. 342(jan11 1). c7258–c7258. 28 indexed citations

19.

Jefferson, Tom, Mark Jones, Peter Doshi, et al.. (2010). Neuraminidase inhibitors for preventing and treating influenza in healthy adults [Intervention Review]. 1–89. 15 indexed citations

20.

Doshi, Peter. (2009). Neuraminidase inhibitors--the story behind the Cochrane review. BMJ. 339(dec07 2). b5164–b5164. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact